New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 6, 2013
07:02 EDTXON, ZIOPZiopharm says committee approves initiation of Phase 1 study of Ad-RTS-IL-12
ZIOPHARM Oncology (ZIOP) announced the unanimous approval of the National Institutes of Health's Recombinant DNA Advisory Committee for the initiation of a Phase 1 study of Ad-RTS-IL-12, an adenoviral vector engineered to express interleukin-12 under the control of veledimex, an oral activator, in subjects with recurrent or progressive glioblastoma or grade III malignant glioma. ZIOPHARM has announced plans to launch a Phase 1 study of Ad-RTS-IL-12 in malignant glioma in the first half of 2014. The Company is currently studying Ad-RTS-IL-12 in Phase 2 studies in melanoma and breast cancer. ZIOPHARM is developing Ad-RTS-IL-12 using Intrexon Corporation's (XON) RheoSwitch Therapeutic System platform to control the expression of interleukin-12 and enable its safe and effective delivery as an anti-tumor agent.
News For ZIOP;XON From The Last 14 Days
Check below for free stories on ZIOP;XON the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ZIOP;XON

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use